Amarillo Biosciences Inc (AMAR) financial statements (2020 and earlier)

Company profile

Business Address AMARILLO BIOSCIENCES INC
AMARILLO, TX 79110-4225
State of Incorp. TX
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4091,2771,980134 2507
Cash and cash equivalents4091,2771,980134 2507
Receivables  5838   
Inventory, net of allowances, customer advances and progress billings4 2315  
Inventory4 2315   
Other current assets      62
Other undisclosed current assets32272476   
Total current assets:4451,3032,084262 25068
Noncurrent Assets
Property, plant and equipment5142744   
Intangible assets, net (including goodwill)146146182156  93
Intangible assets, net (excluding goodwill)146146182156  93
Total noncurrent assets:151160209200  93
TOTAL ASSETS:5971,4642,294463 250162
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:209115159166  288
Other undisclosed accounts payable and accrued liabilities209115159166  288
Due to related parties100105777188  78
Other undisclosed current liabilities445513886920  4,578
Total current liabilities:7537341,8231,273  4,944
Noncurrent Liabilities
Other undisclosed liabilities     452 
Total liabilities:7537341,8231,273 4524,944
Stockholders' equity
Stockholders' equity attributable to parent(157)730471(810)  (4,783)
Preferred stock      0
Common stock405391232219  733
Additional paid in capital4,2083,5272,123238  31,969
Accumulated deficit(4,770)(3,188)(1,884)(1,267)  (37,484)
Total stockholders' equity:(157)730471(810)  (4,783)
TOTAL LIABILITIES AND EQUITY:5971,4642,294463 452162

Income statement (P&L) ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues1278251 2  
Revenue, net  2  
Cost of revenue(9)(65)(60)  (0) 
Cost of goods and services sold     (0) 
Gross profit:313191 2(0) 
Operating expenses(1,583)(1,348)(580)(667)(32)(1)(1,000)
Other undisclosed operating income (loss)  (191)   433
Operating loss:(1,580)(1,335)(580)(667)(30)(1)(566)
Interest and debt expense (4)(38)(3)  (61)
Loss before gain (loss) on sale of properties:(1,580)(1,339)(617)(670)(30)(1)(627)
Other undisclosed net income      4
Net loss:(1,580)(1,339)(617)(670)(30)(1)(623)
Other undisclosed net loss attributable to parent(1)      
Net loss attributable to parent:(1,581)(1,339)(617)(670)(30)(1)(623)
Other undisclosed net loss available to common stockholders, basic      (32)
Net loss available to common stockholders, diluted:(1,581)(1,339)(617)(670)(30)(1)(655)

Comprehensive Income ($ in thousands)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(1,580)(1,339)(617)(670)(30)(1)(623)
Comprehensive loss, net of tax, attributable to parent:(1,580)(1,339)(617)(670)(30)(1)(623)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: